HERCEPTIN 150MG VIAL – Targeted Therapy for HER2-Positive Cancers

Herceptin 150mg Vial, containing Trastuzumab, is a specialized medication used in the treatment of specific types of cancer that overexpress the HER2 protein.
As a monoclonal antibody, Herceptin works by specifically targeting and blocking the HER2 receptor, which can be found in high amounts on the surface of some cancer cells, stimulating their growth and division.
This targeted approach helps to inhibit cancer cell proliferation and can improve patient outcomes in certain HER2-positive breast and gastric cancers.

Product Details

Brand: HERCEPTIN
Principle: Trastuzumab
Strength: 150mg per vial
Form: Powder for concentrate for solution for infusion
Manufacturer: Roche
Legal Status: Prescription Only Medicine (POM)
Storage: Store in a refrigerator (2°C - 8°C).

Key Benefits

• Targets HER2-positive cancer cells specifically, minimizing impact on healthy cells.
• Proven efficacy in treating HER2-positive early-stage and metastatic breast cancer.
• Effective in treating HER2-positive metastatic gastric or gastro-oesophageal junction adenocarcinoma.
• Can be used alone or in combination with chemotherapy, depending on the specific cancer and stage.
• Contributes to improved survival rates and disease-free survival in eligible patients.

How to Use

1. Herceptin 150mg Vial is intended for intravenous administration only.
2. It must be reconstituted and diluted by a trained healthcare professional before use.
3. The appropriate dose and regimen (e.g., weekly or every three weeks) will be determined by your doctor based on your body weight and specific condition.
4. Administration should take place in a clinical setting under the supervision of an oncologist or experienced healthcare provider.
5. Do not self-administer Herceptin.

Caution & Warnings

• Cardiac Dysfunction: Herceptin can cause heart problems, including reduced heart function and congestive heart failure. Regular cardiac monitoring is essential during and after treatment.
• Infusion-Related Reactions: Severe reactions can occur during or after infusion, including fever, chills, nausea, vomiting, pain, headache, and shortness of breath. Medical supervision is crucial during administration.
• Pulmonary Toxicity: Serious lung problems, including acute respiratory distress syndrome, interstitial pneumonitis, and pulmonary fibrosis, have been reported.
• Embryo-Fetal Toxicity: Herceptin can cause harm to a fetus. Pregnant women should not use Herceptin, and women of childbearing potential should use effective contraception during and for 7 months after treatment.
• Hypersensitivity Reactions: Allergic reactions are possible; immediate medical attention may be required.
• Always inform your doctor about all medications you are taking, including over-the-counter drugs and supplements.

Ingredients

Active Ingredient: Trastuzumab (150mg)
Excipients: Sucrose, Polysorbate 20, Histidine (exact excipients may vary slightly by formulation and region; refer to the package leaflet for precise details).